Toggle Menu
Join our Community
Support ToI and remove
all
ads
Learn more
English
Français
עברית
Get The Daily Edition
Account
Sign In
Sign in
Join our Community
Open Search form
Toggle Menu
Israel & the Region
Jewish Times
Israel Inside
Tech Israel
Real Estate
Israel
The Blogs
Podcasts
Video
Newsletters
The Daily Edition
What Matters Most Today
Tech Israel
Updates from Silicon Wadi
Real Estate Israel
Monthly Update
The Weekend Edition
The Best Reads of the Week
Weekly Highlights
Choice Voices From The Blogs
Partners
Atlanta
Atlanta Jewish Times
North New Jersey
The Jewish Standard
Pittsburgh
Jewish Chronicle
United Kingdom
The Jewish News
Australia
The Australian Jewish News
For Publishers
Become a Partner
Open Search form
Toggle Menu
search
Input search
Clear search input
English
Français
עברית
Latest Articles
Latest Alerts
Israel & the Region
Jewish Times
Israel Inside
Tech Israel
Real Estate
Israel
The Blogs
Podcasts
Video
Newsletters
The Daily Edition
What Matters Most Today
Tech Israel
Updates from Silicon Wadi
Real Estate Israel
Monthly Update
The Weekend Edition
The Best Reads of the Week
Weekly Highlights
Choice Voices From The Blogs
Partners
Atlanta
Atlanta Jewish Times
North New Jersey
The Jewish Standard
Pittsburgh
Jewish Chronicle
United Kingdom
The Jewish News
Australia
The Australian Jewish News
For Publishers
Become a Partner
Community
Join our community
Sign in
About The Times of Israel
Advertise on The Times of Israel
Contact us
Download our App
For IOS users
For Android users
Get the Daily Edition
submit
Follow us
© 2026 The Times of Israel , All Rights Reserved
Terms and conditions
Privacy policy
Input search
Clear search input
×
MARILYNN MARCHIONE
February 25, 2021, 12:47 am
Study of Pfizer in Israel shows 72% effective at preventing death after 1st dose
‘Real world’ data analyzing 600,000 vaccinations published by New England Journal of Medicine also finds shots just as effective in over 70s as young people, prevented infection
By
MARILYNN MARCHIONE
February 18, 2021, 3:06 pm
US life expectancy drops a year in pandemic, most since WWII
Expert says final figures expected to be even worse; minorities suffer the biggest impact
By
MARILYNN MARCHIONE
February 8, 2021, 9:32 pm
New virus variants raise concern over COVID-19 reinfections
How long immunity lasts from natural infection is one of the big questions of the pandemic. Recent global developments have scientists worried that the calculation is changing
By
MARILYNN MARCHIONE
January 19, 2021, 8:53 am
A new COVID-19 challenge: Mutations rise along with cases
Each new infection gives the virus a chance to mutate as it makes copies of itself, threatening to undo the progress made so far to control the pandemic
By
MARILYNN MARCHIONE
December 21, 2020, 3:01 am
How worried do we need to be about new coronavirus strains?
As a new, highly infectious strain sweeps across the UK, experts say that at this stage it’s unlikely it will undermine the vaccines
By
MARILYNN MARCHIONE
December 8, 2020, 9:25 pm
Trial results show AstraZeneca coronavirus vaccine 70% effective
But questions remain about ability to protect those over 55; health officials around the world hope to rely on shot because of its low cost, availability and ease of use
By
MARILYNN MARCHIONE
November 22, 2020, 5:04 am
US regulator gives emergency approval to antibody drug used on Trump
FDA allows use of experimental Regeneron treatment for COVID-19 patients at high risk of developing severe illness
By
MARILYNN MARCHIONE
October 30, 2020, 7:45 pm
Study testing COVID antibody drug used to treat Trump halted for some patients
Regeneron Pharmaceuticals says it will stop enrolling seriously ill patients, who need intense oxygen treatment or breathing machines, in trial over safety concerns
By
MARILYNN MARCHIONE
October 23, 2020, 6:46 am
FDA approves first COVID-19 drug: antiviral remdesivir
Medicine found to cut recovery time by five days on average, but no studies have shown it improves chances of surviving the coronavirus
By
MARILYNN MARCHIONE
October 8, 2020, 3:02 am
Ethicists say Trump special treatment raises fairness issues
US resident given rare access to experimental drug; questions also raised as to quality of treatment, with many details on his condition withheld from public
By
MARILYNN MARCHIONE
October 3, 2020, 3:51 am
Trump gets experimental drug aimed at curbing severe illness
Antibody cocktail is in late-stage testing and its safety and effectiveness are not yet known, but maker Regeneron says it might reduce the period symptoms last
By
MARILYNN MARCHIONE
October 2, 2020, 9:19 pm
Trump’s age, health woes raise his risk level in COVID-19 illness
At 74, president’s age would be the primary risk factor, says infectious disease expert; Trump’s also obese, with a BMI over 30, which lowers immunity to virus
By
MARILYNN MARCHIONE
September 27, 2020, 8:18 pm
Million who died of COVID-19 also illuminated treatment
Many more deaths expected as infections surge in US and elsewhere, but there are signs death rate is declining, partially due to hard-fought medical advances
By
MARILYNN MARCHIONE
September 16, 2020, 6:43 pm
Study suggests antibody drug may cut COVID-19 hospitalizations
While tests of drug fell short of main goals, Eli Lilly says results hinting fewer people with virus may need to be hospitalized are an encouraging ‘proof of principle’
By
MARILYNN MARCHIONE
July 30, 2020, 9:09 am
Scientists get closer to blood test for Alzheimer’s disease
Testing identifies people with disease with accuracy ranging from 89% to 98%, but scientists warn new approach still needs more validation
By
MARILYNN MARCHIONE
Load More
Advertisement
close popup
Sign in or Join The Times of Israel Community
Sign in or Register
Paying ToI Community members are invited to comment on articles
Email address
*
Please use the following structure: example@domain.com
Continue
Or Continue with
By joining you agree to the
terms and conditions
Send me The Times of Israel Daily Edition
back
close popup
Register to continue
Email address
*
Change
REGISTER
Or Continue with
back
close popup
Log in to continue
Email address
*
Something went wrong.
Please try again in a few minutes..
Continue
back
close popup
Sign in or Join The Times of Israel Community
Sign in or Register
You are currently registered. Please join The Times of Israel Community to comment and enjoy other Community benefits
Only ToI Community members can comment below articles
Email address
*
Password
*
Incorrect password. Please try again or choose an option below.
Forgot your password?
/
Send me a login link
Continue
Sign in without joining
Or Continue with
close popup
Check your email
We sent an email to you at
.
It has a link that will sign you in.
Click the link in that email to complete registration so you can comment.
back
close popup
Join The Times of Israel Community
Commenting is available for paying members of The Times of Israel Community only. Please join our Community to comment and enjoy other Community benefits.
Email address
*
Please use the following structure: example@domain.com
JOIN NOW!
close popup
Thank you! Now check your email
You are now a member of The Times of Israel Community! We sent you an email with a login link to
. Once you're set up, you can start enjoying Community benefits and commenting.
Back to top
Never miss breaking news on Israel
Get notifications to stay updated
Stay updated
No thanks
You're subscribed
close popup
Register for free
and continue reading
Registering allows you to manage your newsletters and alerts and helps us improve your experience. It takes just a few seconds.
Already registered? Enter your email to sign in.
Email address
Please use the following structure: example@domain.com
REGISTER OR SIGN IN
Or Continue with
By registering you agree to the
terms and conditions
. Once registered, you’ll receive our Daily Edition email for free.
Send me The Times of Israel Daily Edition
back
close popup
Register to continue
Email address
Change
REGISTER
Or Continue with
back
close popup
Log in to continue
Email address
Something went wrong.
Please try again in a few minutes..
Continue
back
close popup
Sign in or Register
Email address
*
Password
*
Incorrect password. Please try again or choose an option below.
Continue
I forgot my password
/
Send me a sign in link
Or Continue with
back
close popup
Check your email
We sent an email to you at
.
It has a link that will sign you in.
Click the link in that email to complete your registration.